Merck
CN
  • Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis.

Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis.

Oncogene (2014-05-20)
J Z Zhou, M A Riquelme, X Gao, L G Ellies, L Z Sun, J X Jiang
摘要

Extracellular ATP has been shown to either inhibit or promote cancer growth and migration; however, the mechanism underlying this discrepancy remained elusive. Here we demonstrate the divergent roles of ATP and adenosine released by bone osteocytes on breast cancers. We showed that conditioned media (CM) collected from osteocytes treated with alendronate (AD), a bisphosphonate drug, inhibited the migration of human breast cancer MDA-MB-231 cells. Removal of the extracellular ATP by apyrase in CM abolished this effect, suggesting the involvement of ATP. ATP exerted its inhibitory effect through the activation of purinergic P2X receptor signaling in breast cancer cells evidenced by the attenuation of the inhibition by an antagonist, oxidized ATP, as well as knocking down P2X7 with small interfering RNA (siRNA), and the inhibition of migration by an agonist, BzATP. Intriguingly, ATP had a biphasic effect on breast cancer cells-lower dosage inhibited but higher dosage promoted its migration. The stimulatory effect on migration was blocked by an adenosine receptor antagonist, MRS1754, ARL67156, an ecto-ATPase inhibitor, and A2A receptor siRNA, suggesting that in contrast to ATP, adenosine, a metabolic product of ATP, promoted migration of breast cancer cells. Consistently, non-hydrolyzable ATP, ATPγS, only inhibited but did not promote cancer cell migration. ATP also had a similar inhibitory effect on the Py8119 mouse mammary carcinoma cells; however, adenosine had no effect owing to the absence of the A2A receptor. Consistently, ATPγS inhibited, whereas adenosine promoted anchorage-independent growth of MDA-MB-231 cells. Our in vivo xenograft study showed a significant delay of tumor growth with the treatment of ATPγS. Moreover, the extent of bone metastasis in a mouse intratibial model was significantly reduced with the treatment of ATPγS. Together, our results suggest the distinct roles of ATP and adenosine released by osteocytes and the activation of corresponding receptors P2X7 and A2A signaling on breast cancer cell growth, migration and bone metastasis.

材料
货号
品牌
产品描述

Sigma-Aldrich
乙腈, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
乙腈, anhydrous, 99.8%
Sigma-Aldrich
DL-二硫代苏糖醇 溶液, BioUltra, for molecular biology, ~1 M in H2O
Sigma-Aldrich
乙腈, ACS reagent, ≥99.5%
Supelco
DL-二硫代苏糖醇 溶液, 1 M in H2O
Sigma-Aldrich
二乙胺, ≥99.5%
Sigma-Aldrich
乙腈, for HPLC, for UV, ≥99.9% (GC)
Sigma-Aldrich
乙腈, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
正己胺, 99%
Sigma-Aldrich
腺苷, ≥99%
Sigma-Aldrich
酚红, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
二乙胺, puriss. p.a., ≥99.5% (GC)
Sigma-Aldrich
酚红, ACS reagent
Supelco
乙腈, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D -荧光素, synthetic
Sigma-Aldrich
乙腈, suitable for HPLC-GC, ≥99.8% (GC)
Sigma-Aldrich
腺苷, suitable for cell culture, BioReagent
Supelco
乙腈, analytical standard
Supelco
腺苷, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
乙腈, biotech. grade, ≥99.93%
Sigma-Aldrich
乙腈, ReagentPlus®, 99%
Sigma-Aldrich
二乙胺, purified by redistillation, 99.5%
Sigma-Aldrich
腺苷
Sigma-Aldrich
乙腈, electronic grade, 99.999% trace metals basis
Supelco
正己胺, analytical standard
Sigma-Aldrich
乙腈, suitable for DNA synthesis, ≥99.9% (GC)
Supelco
残留溶剂-乙腈, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
乙腈, ≥99.5% (GC)
Sigma-Aldrich
D -荧光素, synthetic, BioXtra, ≥99% (HPLC)
USP
二类残留溶剂 - 甲醇, United States Pharmacopeia (USP) Reference Standard